Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conor gets six-month study boost for drug-eluting CoStar stent; firm forms multi-drug pact with novartis

This article was originally published in Clinica

Executive Summary

Six-month follow-up results from a pivotal European trial of Conor Medsystems' cobalt chromium paclitaxel-eluting stent, CoStar, have shown consistently low restenosis and complication rates for the product across an array of patients. So reported the Menlo Park, California company, which also recently signed a deal to evaluate the delivery of different drugs from its stents.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel